<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of graft-versus-host disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of graft-versus-host disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of graft-versus-host disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert Zeiser, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert S Negrin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 16, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Graft-versus-host disease (GVHD) can develop after allogeneic hematopoietic cell transplantation (HCT), when immune cells from the transplant donor (the graft) initiate an immune reaction against the transplant recipient (the host). Acute GVHD and chronic GVHD are multisystem disorders that are distinguished by their clinical findings, according to the widely-accepted National Institutes of Health (NIH) consensus criteria; an overlap syndrome with features of both acute GVHD and chronic GVHD is also recognized.</p><p>Prevention of GVHD is discussed in this topic.</p><p>Other aspects of GVHD are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3550.html" rel="external">"Treatment of chronic graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">"Pathogenesis of graft-versus-host disease (GVHD)"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW OF GVHD AND ITS PREVENTION</span><span class="headingEndMark"> — </span>GVHD can develop after allogeneic hematopoietic cell transplantation (HCT), when immune cells from an immunologically non-identical donor (the graft) initiate an immune reaction against the transplant recipient (the host). The incidence and severity of GVHD vary with the degree of immunologic mismatch, aspects of the transplantation procedure, and patient risk factors. Effective prophylaxis can decrease the incidence of GVHD, but it does not eliminate it entirely.</p><p>Acute GVHD (aGVHD) and chronic GVHD (cGVHD) are multisystem disorders that share some features, but they can be distinguished by clinical findings, affected organs, and underlying pathophysiology. The syndromes are classified and severity is graded according to the widely-accepted National Institutes of Health (NIH) consensus criteria; an overlap syndrome with features of both aGVHD and cGVHD is also recognized [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute GVHD – </strong>aGVHD classically presents in the early post-transplantation period (eg, first 100 days), although it can present later. It is initiated by tissue damage to the gastrointestinal (GI) tract caused by the conditioning regimen, which enables translocation of intestinal flora and causes a T lymphocyte-mediated/cytokine-driven inflammatory syndrome that is bolstered by macrophages, neutrophils, and dendritic cells. Clinical manifestations primarily affect skin, GI tract, and liver. Greater severity of aGVHD is associated with an increased risk of mortality, but despite routine administration of prophylaxis, clinically significant aGVHD develops in up to one-half of transplant recipients, especially when the donor and recipient have greater immunologic differences. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic GVHD – </strong>cGVHD is a major cause of late morbidity and mortality after allogeneic HCT. It generally presents ≥100 days after transplantation with fibrosis and chronic inflammation of the skin, lungs, GI tract, and soft tissues; the protean manifestations of cGVHD resemble immune-mediated disorders. cGVHD has a complex pathophysiology that involves early inflammation from the conditioning regimen, activation of donor T cells, and injury of vascular endothelium that facilitates migration of donor-derived T and B lymphocytes into host tissues. Aberrant repair mechanisms foster activation of fibroblasts, collagen deposition, and fibrosis that can lead to irreversible end-organ injury and dysfunction. More than one-third of patients who undergo allogeneic HCT develop clinically significant cGVHD, but the incidence and severity vary according to the degree of immunologic mismatch, transplant conditions, and other risk factors.</p><p></p><p>The immunologic mechanisms that cause GVHD are also responsible for the graft-versus-tumor (GVT) effect, which is important for eradicating an underling malignancy. Treatments that limit GVHD can diminish the GVT effect and may increase the likelihood of recurrent disease. As such, the application of GVHD prophylaxis must balance the benefit of reducing GVHD with the potential harm of decreasing the GVT effect. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methods of prophylaxis</strong> – Prophylaxis for GVHD focuses on inhibition of donor T cells using pharmacologic agents, with or without in vivo or ex vivo T cell depletion. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic inhibition</strong> – The mainstay of pharmacologic GVHD prophylaxis is a combination of a calcineurin inhibitor (CNI; ie, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> or <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) plus an antimetabolite (eg, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [MMF]). (See <a class="local">'Immunosuppressive backbone'</a> below.) </p><p></p><p class="bulletIndent2">In many cases, other agents may be added to this backbone or substituted, as described below. (See <a class="local">'Selection of a GVHD prophylaxis regimen'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>T cell depletion (TCD)</strong> – T lymphocytes are essential components of GVHD pathophysiology. TCD can be accomplished with in vivo or ex vivo techniques, as described below. (See <a class="local">'T cell depletion (TCD)'</a> below.)</p><p></p><p class="bulletIndent1">Preferred approaches for prophylaxis are guided by features of the transplantation technique and risk factors, as described below. (See <a class="local">'GVHD prophylaxis'</a> below.)</p><p></p><p class="headingAnchor" id="H124062230"><span class="h1">GVHD PROPHYLAXIS</span><span class="headingEndMark"> — </span>Preferred approaches for GVHD prophylaxis vary with transplant conditions (eg, degree of immunologic match, conditioning regimen, graft source, and other factors), institutional practice, and clinical trial protocol [<a href="#rid2">2</a>]. Nevertheless, each institution must have guidelines for the prevention and management of GVHD that are approved by international accrediting organizations for transplant centers (Joint Accreditation Committee for ISCT Europe and EBMT [JACIE] and Foundation for the Accreditation of Cell Therapy [FACT]). Guidelines for GVHD prophylaxis have been proposed by the European Group for Blood and Marrow Transplantation (EBMT) and European LeukemiaNet  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. Our approach is generally consistent with these guidelines.</p><p class="headingAnchor" id="H2129813768"><span class="h2">Immunosuppressive backbone</span><span class="headingEndMark"> — </span>For GVHD prophylaxis, we suggest a calcineurin inhibitor (CNI) plus an antimetabolite, rather than a CNI alone or an antimetabolite alone. This suggestion is based on superior survival and less acute GVHD (aGVHD) with the combination, compared with either agent alone. </p><p>Most often, either <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (Tac) or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (CsA) is the CNI, while the antimetabolite is either <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>).  </p><p>Evidence that supports the use of a combination of a CNI plus an antimetabolite include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNI plus an antimetabolite is superior to a CNI alone</strong> – The combination of a CNI plus an antimetabolite achieves superior survival and a lower incidence of aGVHD, compared with a CNI alone.</p><p></p><p class="bulletIndent1">A phase 3 trial reported that overall survival (OS) was higher and the incidence of aGVHD was lower with CsA plus MTX, compared with CsA alone [<a href="#rid4">4</a>]. The trial of 93 patients undergoing myeloablative conditioning (MAC) allogeneic hematopoietic cell transplantation (HCT) using matched sibling donor (MSD) grafts reported that 15-month OS was higher with CsA/MTX (80 versus 55 percent) compared with CsA alone; this difference corresponds to a 2.4-fold relative risk (RR) for death with CsA alone. CsA/MTX was also associated with less grade ≥2 aGVHD (33 versus 54 percent); the RR for CsA alone was 2.06 (95% CI 1.08-3.88); there was no grade 4 aGVHD with CsA/MTX, compared with grade 4 aGVHD in seven patients who received CsA alone. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CNI plus an antimetabolite is superior to an antimetabolite alone</strong> – The combination a CNI plus an antimetabolite is associated with less aGVHD and a trend toward improved survival, compared with an antimetabolite alone. </p><p></p><p class="bulletIndent1">A trial that randomly assigned 46 patients undergoing MAC HCT to CsA/MTX versus MTX alone reported better outcomes with the combination regimen [<a href="#rid5">5</a>]. Compared with MTX alone, there was a trend toward improved two-year OS with the combination (82 versus 60 percent) and there was less grade 2-4 aGVHD (18 versus 53 percent), fewer infections, and similar rate of chronic GVHD (cGVHD). No patients given CsA/MTX prophylaxis developed grade 3-4 aGVHD, while MTX alone was associated with grade 3 aGVHD in three patients and grade 4 aGVHD in six patients. One patient in each trial arm did not successfully engraft. With longer follow-up (three to six years), neither four-year OS (73 percent with CsA/MTX versus 58 percent with MTX alone) nor incidence of cGVHD (58 versus 38 percent, respectively) differed significantly between trial arms [<a href="#rid6">6</a>].</p><p></p><p>Other studies also support the conclusion that a combination of a CNI plus an antimetabolite is superior to monotherapy for GVHD prophylaxis [<a href="#rid7">7-10</a>]. </p><p>Specific prophylaxis regimens vary according to the degree of immunologic match, conditioning regimen, graft source, and recipient factors, as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunologic match:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Matched sibling (related) donor </strong>– (See <a class="local">'Matched sibling donor (MSD)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Matched unrelated donor</strong> – (See <a class="local">'Matched unrelated donor (MUD)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Haploidentical (haplo) donor</strong> – (See <a class="local">'Haploidentical donor'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mismatched unrelated donor or umbilical cord blood</strong> – (See <a class="local">'Other alternative donors'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conditioning regimen:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myeloablative conditioning</strong> – (See <a class="local">'Myeloablative conditioning (MAC)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-MAC regimens </strong>(ie, reduced intensity conditioning [RIC] or non-myeloablative [NMA] conditioning) – (See <a class="local">'Non-MAC regimens'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral blood stem/progenitor cell (PBSPC) graft</strong> – (See <a class="local">'Peripheral blood grafts'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other considerations</strong> – Special consideration may apply for patients with high-risk for GVHD (eg, greater immunologic mismatch, older age, sex disparity between donor and recipient, prior donor alloimmunization, cytomegalovirus [CMV] serostatus disparity), intolerance for certain agents (eg, use of MTX in patients with limited kidney function or fluid collections), or a need for rapid engraftment (eg, patients with aspergillosis). (See <a class="local">'Other considerations'</a> below.)</p><p></p><p class="headingAnchor" id="H1686866726"><span class="h2">Selection of a GVHD prophylaxis regimen</span></p><p class="headingAnchor" id="H1473646436"><span class="h3">Immunologic match</span><span class="headingEndMark"> — </span>Preferences for GVHD prophylaxis vary according to the degree of immunologic match.</p><p class="headingAnchor" id="H3897604799"><span class="h4">Matched sibling donor (MSD)</span><span class="headingEndMark"> — </span>For HCT with a human leukocyte antigen (HLA)-matched sibling/related donor, we suggest MTX plus either Tac or CsA. This suggestion is based on similar survival with MTX plus either CNI, but Tac is generally associated with a lower incidence of aGVHD, according to randomized trials and retrospective studies [<a href="#rid11">11-14</a>]. </p><p>The choice of Tac versus CsA is largely guided by institutional preference, as they have similar efficacy and toxicity. Studies that compared Tac versus CsA are described below. (See <a class="local">'Choice of CNI'</a> below.)</p><p class="headingAnchor" id="H1538777886"><span class="h4">Matched unrelated donor (MUD)</span><span class="headingEndMark"> — </span>For HCT using an MUD (ie, ≥9/10 or ≥7/8 HLA alleles), we suggest adding antithymocyte globulin (ATG) to MTX plus a CNI, rather than MTX/CNI without ATG. In randomized trials, survival was similar with or without added ATG, but patients who received ATG had a lower incidence of cGVHD and required less immunosuppressive therapy.</p><p>Administration of ATG is discussed below. (See <a class="local">'Antithymocyte globulin (ATG)'</a> below.)</p><p>Trials of GVHD prophylaxis using MUD grafts include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addition of ATG to standard prophylaxis for MUD grafts </strong>– Addition of ATG to standard prophylaxis (ie, CNI plus an antimetabolite) does not affect OS, but it reduces cGVHD and enables more patients to discontinue immunosuppressive drugs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A systematic review and meta-analysis of six randomized trials (845 total patients) concluded that including ATG in the GVHD prophylaxis regimen decreased GVHD and enabled more patients to discontinue immunosuppressive drugs, but it did not improve survival [<a href="#rid15">15</a>]. There was no significant difference in rates of OS, engraftment, relapse, or nonrelapse mortality (NRM), based on use of ATG. However, ATG was associated with less aGVHD (RR 0.75 [95% CI 0.65-0.88]); subset analysis noted this association for grade 2-4 and grade 3-4 aGVHD and with both bone marrow (BM) and peripheral blood (PB) graft sources. ATG use was also associated with less cGVHD (RR 0.54 [95% CI 0.44-0.66]) and a lower incidence of extensive cGVHD (RR 0.32 [95% CI 0.22-0.45]) with both BM and PB graft sources. There was more reactivation of CMV and Epstein-Barr virus (EBV) with ATG, but no difference in bacterial infections, rate of engraftment, or post-transplant lymphoproliferative disorder (PTLD). ATG was associated with modest delays in neutrophil and platelet engraftment (median of 2.7 and 7.5 days, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An earlier Cochrane meta-analysis of six randomized controlled trials (568 participants) also reported that ATG did not affect OS, but it was associated with less treatment-requiring or grade 2-4 aGVHD (RR 0.68 [95% CI 0.55-0.85]) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Examples of phase 3 trials that evaluated outcomes with ATG include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A multicenter phase 3 trial randomly assigned 161 patients to CsA/MTX, with or without ATG, for MAC HCT in acute leukemia [<a href="#rid17">17</a>]. With median follow-up of two years, ATG resulted in less cGVHD (32 versus 69 percent) and a higher percentage of patients who could discontinue CsA (91 versus 39 percent). The two cohorts had similar rates of OS, relapse-free survival (RFS), aGVHD, reactivation of CMV and EBV, and there were no cases of PTLD. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a multicenter trial of 203 patients undergoing MAC or non-MAC HCT from an unrelated donor (UD) for a hematologic malignancy, patients assigned to ATG were more likely to be free from immunosuppressive treatment at 12 months (37 versus 16 percent) and had less cGVHD, but there was no difference between trial arms in OS, NRM, relapse, graft failure, or severity of aGVHD [<a href="#rid18">18</a>]. EBV reactivation was more common with ATG (20 versus 2 patients) and one patient who received ATG died from EBV reactivation. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Similar findings were reported in another phase 3 trial; longer-term follow-up noted that the lower incidence of cGVHD and less need for immunosuppressive therapy that persisted after eight years [<a href="#rid19">19,20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival is similar with Tac versus CsA for MUD grafts </strong>– In a phase 3 trial of 180 patients receiving MUD grafts, MTX plus Tac versus CsA did not differ regarding OS, RFS, toxicity, infections, or leukemia relapse, but Tac was associated with less grade 2-4 aGVHD (56 versus 74 percent) [<a href="#rid11">11</a>].  </p><p></p><p class="headingAnchor" id="H1873032190"><span class="h4">Haploidentical donor</span><span class="headingEndMark"> — </span>For haploidentical (haplo) HCT, we suggest adding post-transplant <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (PTCy) to a CNI plus MMF, rather than other immunosuppressive regimens. This suggestion is based on less GVHD, fewer relapses, less NRM, and a trend toward improved survival with PTCy. </p><p>Treatment with PTCy is described below. (See <a class="local">'Post-transplant cyclophosphamide (PTCy)'</a> below.)</p><p>PTCy was superior to antithymocyte globulin (ATG) in a retrospective cooperative group study of haplo HCT in patients with acute myeloid leukemia (AML) in remission [<a href="#rid21">21</a>]. The study compared 193 patients who received PTCy-based prophylaxis versus 115 who were treated with ATG-based prophylaxis; approximately half of patients received MAC HCT. Patients in the PTCy group also received MMF and CsA (62 percent) or MMF and Tac (28 percent), while those in the ATG group also received three to five other drugs, including CsA, MTX, and/or <a class="drug drug_general" data-topicid="8803" href="/z/d/drug information/8803.html" rel="external">basiliximab</a>. Compared with ATG-based prophylaxis, patients treated with PTCy had less grade 3-4 aGVHD (5 versus 12 percent, respectively) and in multivariate analysis, PTCy was also associated with superior GVHD-free/RFS (GRFS; hazard ratio [HR] 1.5 [95% CI 1.0-2.0]), leukemia-free survival (LFS; HR 1.5 [95% CI 1.0-2.1]), and NRM (HR 1.8 [95% CI 1.1-2.9]); there was a trend toward improved two-year OS (HR 1.43 [95% CI 0.98-2.09]) with PTCy. </p><p>Studies with PTCy for haplo HCT using both MAC and non-MAC (RIC or NMA conditioning) regimens include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-MAC (ie, RIC or NMA):</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective analysis of 271 adults (50 to 75 years) who received PTCy for non-MAC, T cell-replete haplo HCT reported aGVHD and cGVHD in 33 and 10 percent of patients, respectively; 3 percent grade 3-4 GVHD; and 8 percent NRM at six months [<a href="#rid22">22</a>]. Rates of severe GVHD, NRM, progression-free survival (PFS), and OS did not differ by age.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single-institution study of 67 patients with hematologic malignancies who were treated with NMA conditioning, haplo grafts, and PTCy-based prophylaxis reported 36 percent two-year OS, 26 percent two-year event-free survival (EFS), 15 percent one-year NRM, and 51 percent one-year relapse [<a href="#rid23">23</a>]. Other outcomes included 87 percent engraftment, 34 percent grade 2-4 aGVHD, and 6 percent grade 3-4 aGVHD, and low rates of cGVHD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MAC</strong> – Historically, haplo grafts using MAC HCT without PTCy were associated with excessive NRM and GVHD. However, since the inclusion of PTCy in the prophylaxis regimen, MAC HCT using haplo grafts is associated with rates of GVHD that are similar to those with standard prophylaxis (CNI plus an antimetabolite) with MSD HCT:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multi-institution study of PTCy for MAC HCT (using <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a> and <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>) in 92 adults (45 with related donors and 47 with unrelated donors) reported two-year rates of OS and disease-free survival (DFS) were 67 and 62 percent, respectively; 51 percent grade 2-4 aGVHD; and 15 percent grade 3-4 aGVHD [<a href="#rid24">24</a>]. Among patients who survived &gt;2 years, the cumulative incidence of cGVHD was 14 percent. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a single-institution study, transplantation of 30 patients using total body irradiation (TBI)-based MAC reported 78 percent two-year OS, 73 percent DFS, 3 percent NRM, and 24 percent relapse [<a href="#rid25">25</a>]. Other outcomes included 43 percent grade 2-4 aGVHD, 23 percent grade 3-4 aGVHD, and 56 percent cGVHD (severe in 10 percent). These outcomes were similar to outcomes in contemporaneous patients who received MAC HCT using MUD grafts. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A registry study of 92 patients who underwent haplo HCT (77 percent MAC) reported 52 percent four-year OS, 18 percent day 1000 treatment-related mortality (TRM), and 18 percent relapse rate [<a href="#rid26">26</a>]. Other outcomes included 14 percent grade 2-4 aGVHD, 4 percent grade 3-4 aGVHD, and 15 percent cGVHD. The proportion of patients who were off CsA by day 180 was 68 percent and was 81 percent after one year. OS with haplo HCT was similar to that of 176 patients who received MSD grafts, while the incidence of grade 2-4 aGVHD was significantly lower with haplo HCT compared with MSD HCT.</p><p></p><p>Tac/MMF/PTCy is currently being compared with Tac/MTX in a phase 3 trial.</p><p class="headingAnchor" id="H3905463934"><span class="h4">Other alternative donors</span><span class="headingEndMark"> — </span>There is no consensus GVHD prophylaxis regimen for other alternative donors, such as mismatched unrelated donor (mMUD) or umbilical cord blood (UCB) grafts. However, the risk for GVHD increases with greater immunologic differences, so we consider donor-graft discordance, conditioning regimen, and risk of relapse in choosing a prophylaxis regimen.</p><p class="headingAnchor" id="H4181136519"><span class="h3">Conditioning regimen</span></p><p class="headingAnchor" id="H1484128579"><span class="h4">Myeloablative conditioning (MAC)</span><span class="headingEndMark"> — </span>For MAC allogeneic HCT, we suggest GVHD prophylaxis using a CNI plus MTX, rather than a CNI plus MMF, based on similar survival but less severe GVHD, according to meta-analyses and retrospective studies. However, some institutions favor MMF to avoid the higher rate of mucositis associated with MTX.</p><p>Treatment with MTX is described below. (See <a class="local">'Methotrexate (MTX)'</a> below.) </p><p>For patients with a contraindication to MTX or who need rapid engraftment (eg, patients with aspergillosis), MMF can be used instead of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. (See <a class="local">'Mycophenolate mofetil (MMF)'</a> below.)</p><p>Meta-analyses reported that, compared with MTX, MMF is associated with similar survival, faster engraftment, less mucositis, but more grade 3-4 aGVHD:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of three randomized controlled trials (RCT; 174 patients analyzed) reported no difference in survival, relapse, aGVHD, cGVHD, or neutrophil engraftment between MMF and MTX [<a href="#rid27">27</a>]. The analysis also noted that there was low-quality evidence that MMF was associated with faster platelet engraftment, a lower incidence of severe mucositis, and less need for pain control and <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis that included RCTs and other studies also reported no difference in survival outcomes, but MMF was associated with less mucositis (RR 0.35 [95% CI 0.25–0.49]) and faster engraftment (mean difference 3.6 days), but more grade 3-4 aGVHD (RR 1.61 [95% CI 1.18–2.30]) [<a href="#rid28">28</a>].  </p><p></p><p>Other informative studies that compared MTX and MMF for MAC HCT include:</p><p class="bulletIndent1"><span class="glyph">●</span>A phase 3 trial in patients undergoing MAC HCT with MSD grafts was terminated early because CsA plus MMF was associated with faster hematopoietic engraftment and less mucositis than CsA plus MTX [<a href="#rid29">29</a>]. Compared with 19 patients who received CsA plus MTX, the 21 patients who received MMF had a lower incidence of severe mucositis (21 versus 65 percent) and a shorter time to neutrophil engraftment (11 versus 18 days); day 100 OS and incidence of aGVHD were similar in both arms. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective analysis of patients who underwent MAC HCT using MSD grafts reported no difference in survival with CsA/MMF versus CsA/MTX, but MMF was associated with more rapid marrow recovery, shorter hospital stays, and more grade 3-4 aGVHD [<a href="#rid30">30</a>]. There were no significant differences in OS, NRM, or relapse, but MMF was associated with faster neutrophil recovery (median 11 versus 19 days) and platelet recovery (median 19 versus 25 days), less severe mucositis (19 versus 53 percent), and shorter length of hospital stay (median 25 versus 36 days). However, multivariate analysis detected increased risk of grade 3-4 aGVHD (HR 2.92 [95% CI 1.2-7.15]), but there were no differences in aGVHD or grade 2-4 cGVHD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized phase 2 study reported no difference in OS, RFS, NRM, relapse, or time to neutrophil recovery among 47 patients treated with Tac plus MTX versus 42 patients treated with Tac plus MMF [<a href="#rid31">31</a>]. Patients who received MMF were less likely to experience severe mucositis, require narcotic analgesia or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>, and had earlier hospital discharge. Grade 2-4 aGVHD at day 100 was similar, but there was more grade 3-4 aGVHD with MMF (19 versus 4 percent); this was predominantly seen with MUD grafts (26 versus 4 percent), as the effects with MSD grafts did not differ significantly (11 versus 4 percent). Platelet recovery was earlier in patients treated with MMF. </p><p></p><p class="headingAnchor" id="H1326403507"><span class="h4">Non-MAC regimens</span><span class="headingEndMark"> — </span>For adults undergoing NMA or RIC allogeneic HCT, we suggest a CNI plus MMF, rather than a CNI plus MTX. No phase 3 trials have directly compared MMF versus MTX in this setting, but a CNI plus MMF has been widely adopted for prophylaxis with NMA or RIC HCT, primarily because it is associated with faster hematologic recovery and less mucositis than MTX and because GVHD is less of a concern with non-MAC regimens compared with MAC HCT. </p><p>PTCy is also being evaluated for non-MAC HCT, as discussed below. (See <a class="local">'Post-transplant cyclophosphamide (PTCy)'</a> below.)</p><p>Studies that compared MTX and MMF for non-MAC HCT include:</p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis reported no differences in OS, DFS, or cGVHD among 1564 adults who underwent RIC allogeneic HCT for leukemia or myelodysplastic syndrome (MDS) [<a href="#rid32">32</a>]. The study compared four cohorts of patients based on GVHD prophylaxis: MMF/Tac, MMF/CsA, MTX/Tac, and MTX/CsA. For recipients of MSD grafts, there were no differences in outcomes, including rates of GVHD. However, for recipients of MUD grafts, compared with MTX/Tac, patients treated with MMF/CsA had a higher rate of NRM (HR 1.48) and a trend toward lower relapse rate (HR 0.53), which did not affect OS. MMF was also associated with more grade 2-4 aGVHD (RR 1.78) and grade 3-4 aGVHD (RR 1.93) but faster neutrophil recovery. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Meta-analyses (which included both non-MAC and MAC HCT) that described similar survival, faster engraftment, less mucositis, but more grade 3-4 aGVHD with MMF compared with MTX are described above [<a href="#rid27">27,28</a>]. (See <a class="local">'Myeloablative conditioning (MAC)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter randomized phase 2 study reported that for patients who underwent RIC HCT, those who received PTCy had superior GRFS compared with other GVHD prophylaxis regimens [<a href="#rid33">33</a>]. Patients were randomly assigned (1:1:1) to: Tac/MMF/PTCy, Tac/MTX/<a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, or Tac/MMF/<a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">maraviroc</a>; each group was compared separately to a control group (a contemporary cohort of 224 patients who met the same eligibility criteria but were treated with Tac/MTX at other institutions). Compared with control patients, those who received PTCy had superior GRFS (HR 0.72 [90% CI 0.54-0.94]), while GRFS for the other treatments did not differ from the control group. Adverse events (AEs) in patients treated with PTCy were similar to the other regimens and were primarily hematologic; there were 13 percent grade 3 and 73 percent grade 4 AEs. Other studies of PTCy for non-haplo HCT are described below. (See <a class="local">'Post-transplant cyclophosphamide (PTCy)'</a> below.)</p><p></p><p class="headingAnchor" id="H2232503118"><span class="h3">Peripheral blood grafts</span><span class="headingEndMark"> — </span>For transplantation using a PB graft source, we consider treatment with either Tac or CsA plus either MTX or MMF acceptable. </p><p>In general, there are no significant differences in outcomes based on the immunosuppressive regimen, although MMF may be associated with more GVHD but faster hematologic recovery: </p><p class="bulletIndent1"><span class="glyph">●</span>A registry study compared outcomes in patients who underwent RIC HCT using MSD or UD PB grafts for leukemia or MDS from 2000 to 2013; the study divided the 1564 adult patients into four cohorts: MMF/Tac, MMF/CsA, MTX/Tac, and MTX/CsA [<a href="#rid32">32</a>]. There was no difference in OS, DFS, or cGVHD among any of the GVHD prophylaxis regimens. However, for the UD group, MMF/CsA was associated with more NRM (HR 1.48) and increased risk of grade 2-4 aGVHD (RR 1.78) and grade 3-4 aGVHD (RR 1.93), compared with MTX/Tac. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study compared outcomes in 456 patients who received MTX plus either Tac or CsA after MAC HCT using granulocyte colony-stimulating factor (G-CSF)-mobilized PB grafts from MSD or MUD donors for hematologic malignancies [<a href="#rid12">12</a>]. Multivariate analysis reported no differences between Tac and CsA for OS, DFS, relapse, NRM, aGVHD, or cGVHD.</p><p></p><p class="headingAnchor" id="H3907939653"><span class="h3">Other considerations</span><span class="headingEndMark"> — </span>Other considerations in choosing a GVHD prophylaxis regimen include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited kidney function or other contraindication to MTX</strong> – For patients with limited renal function or a fluid collection that precludes use of MTX, MMF and/or <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> can be considered for prophylaxis. (See <a class="local">'Mycophenolate mofetil (MMF)'</a> below and <a class="local">'Sirolimus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for rapid engraftment</strong> – For patients in whom rapid engraftment is a high priority (eg, patients with aspergillosis), MMF can be used instead of MTX. (See <a class="local">'Mycophenolate mofetil (MMF)'</a> below.)</p><p></p><p class="headingAnchor" id="H6"><span class="h1">CALCINEURIN INHIBITORS (CNI)</span><span class="headingEndMark"> — </span>The primary pharmacologic strategy to prevent GVHD is inhibition of the cytoplasmic enzyme, calcineurin. T cell activation is highly dependent on calcineurin and calcium-dependent signal transduction pathways downstream of the T cell receptor (TCR)  (<a class="graphic graphic_figure graphicRef60611" href="/z/d/graphic/60611.html" rel="external">figure 1</a>). The CNIs, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (Tac) and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (CsA), are structurally distinct, but they have similar mechanisms of action:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TCR signaling</strong> – In T lymphocytes, the activation cascade downstream from the TCR includes binding of calcium to calmodulin, which in turn, leads to binding of calmodulin to calcineurin. Activated calcineurin dephosphorylates the cytoplasmic unit of nuclear factor of activated T cells (NF-AT), which enables translocation of NF-AT from the cytoplasm into the nucleus and renders it competent to activate transcription of genes that encode key lymphocyte cytokines, including interleukin (IL)-2, tumor necrosis factor (TNF)-alpha, IL-3, IL-4, CD40L, granulocyte-macrophage colony-stimulating factor, and interferon-gamma [<a href="#rid34">34,35</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Both CsA and Tac bind cyclophilin-related proteins (ie, cyclophilin and FK binding proteins [FKBP], respectively). The CNI-cyclophilin complex binds and inhibits calcineurin, which blocks nuclear translocation and transcriptional activation of NF-AT, and proliferation of T lymphocytes [<a href="#rid34">34,35</a>]. </p><p></p><p>Additional details of CNI activity are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Mechanism of action'</a>.)</p><p class="headingAnchor" id="H354926615"><span class="h2">Choice of CNI</span><span class="headingEndMark"> — </span>Tac and CsA have similar clinical properties, efficacy, and toxicity. Selection of a CNI for GVHD prophylaxis in allogeneic hematopoietic cell transplantation (HCT) is largely guided by institutional preference. </p><p>Common adverse effects (AEs) of CNIs include hypomagnesemia, hyperkalemia, hypertension, and nephrotoxicity. Rarely, these CNIs are associated with life-threatening complications of transplant-associated thrombotic microangiopathy (TA-TMA) and neurotoxicity. (See  <a class="medical medical_review" href="/z/d/html/114693.html" rel="external">"Thrombotic microangiopathies (TMAs) with acute kidney injury (AKI) in adults: CM-TMA and ST-HUS"</a>.)</p><p>Monitoring and management of CNI levels in blood are important for optimal efficacy and toxicity; other nephrotoxic drugs should be avoided, when possible, to enable delivery of the CNI at the target dose. For patients with limited kidney function or if nephrotoxicity occurs with a CNI, alternative agents can be employed. (See <a class="local">'Other considerations'</a> above.)</p><p>Phase 3 trials and registry studies that compared prophylaxis with an antimetabolite plus either Tac or CsA reported similar outcomes, but Tac is generally associated with less acute GVHD (aGVHD).</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase 3 trial of HCT using unrelated donor grafts, the outcomes, efficacy, and toxicity were similar when patients were treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) in combination with either Tac or CsA [<a href="#rid13">13</a>]. CNI doses were adjusted to achieve Tac (15 ng/mL) or CsA (500 ng/mL); &gt;90 percent of patients achieved serum concentrations of 80 to 120 percent of the target concentration in the first four weeks after HCT. Overall survival (OS), disease-free survival (DFS), incidence of relapse, nonrelapse mortality (NRM), and organ toxicities were equivalent with either CNI. Rates of aGVHD were also similar; Tac was associated with 33 percent grade 2-4 aGVHD and 9 percent grade 3-4 aGVHD, compared with 40 percent and 8 percent, respectively, with CsA. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a phase 3 trial of 180 patients undergoing allogeneic HCT with matched unrelated donor (MUD) grafts, outcomes did not differ with MTX/Tac versus MTX/CsA [<a href="#rid11">11</a>]. There were no significant differences in OS, relapse-free survival (RFS), toxicity, infections, or leukemia relapse. However, Tac was associated with less grade 2-4 aGVHD (56 versus 74 percent) and less need for glucocorticoids to manage GVHD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A phase 3 trial of 45 patients with hematologic malignancies who received matched sibling donor (MSD) grafts reported that MTX/Tac was associated with less aGVHD, but MTX/CsA was associated with better survival; however, interpretation of the outcomes is limited because more patients in the MTX/CsA had advanced disease [<a href="#rid14">14</a>]. Compared with CsA, patients who received Tac had less grade 2-4 GVHD (32 versus 44 percent), but a similar incidence of grade 3-4 aGVHD (17 versus 13 percent); incidence of chronic GVHD (cGVHD) was similar (56 versus 49 percent), but CsA was associated with more clinically extensive cGVHD. Patients treated with MTX/CsA had better two-year OS (57 versus 47 percent) and two-year DFS (50 versus 41 percent), but these differences were largely due to inferior outcomes in patients with advanced disease; OS was 25 percent with Tac versus 42 percent with CsA and DFS was 20 percent with Tac versus 28 percent with CsA. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 456 patients reported no differences in OS, DFS, NRM, relapse, aGVHD, or cGVHD for patients who received Tac versus CsA [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H263518200"><span class="h3">Cyclosporine (CsA)</span><span class="headingEndMark"> — </span>CsA is a neutral hydrophobic cyclic peptide composed of 11 amino acids that was originally extracted from soil fungi. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The initial dose of CsA is 3 mg/kg/day, given as a short intravenous (IV) bolus infusion in two daily doses beginning on day –2 or –1  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>). It is usually given IV for the first several weeks to allow healing of the oral mucosa and gastrointestinal (GI) tract after conditioning therapy. CsA prophylaxis is continued for six months in the absence of GVHD  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">CsA administration is changed to the oral route when eating and drinking occur without significant difficulties. CsA is available as a solution and as soft gelatin capsules. CsA is administered in two daily oral doses; the first oral dose is twice the IV dose. Food (especially high fat content foods) may influence CsA bioavailability. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – CsA levels are monitored to guide dosing until approximately day +100. Trough levels are measured 12 hours after a dose. Many drugs can increase or decrease CsA levels. CsA can also leach into plastic catheters, so it is important that the lumen used to measure plasma levels is separate from the lumen through which <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> is infused; otherwise, serum levels are likely to be falsely elevated. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target levels</strong> – The target concentration for CsA varies over time from transplantation:<strong> </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>First three to four weeks after HCT</strong> – A target concentration of 200 to 300 mg/mL is used during the first three to four weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Subsequent monitoring</strong> – If there is no GVHD after three to four weeks, the target concentration is decreased to 100 to 200 mg/mL until three months after transplantation; CsA is then tapered further, as described below.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dose adjustment </strong>– The dose of CsA should be increased if levels are below the therapeutic threshold. If levels are modestly elevated in an asymptomatic patient, no dose adjustment is needed. However, if levels are &gt;2 times the upper limit of the therapeutic range, the dose should be reduced to avoid seizures and other neurotoxicity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tapering</strong> – Tapering of CsA varies according to the degree of immunologic match and recipient age; a slower taper may be preferable in older patients.</p><p></p><p class="bulletIndent1">The dose of CsA should not be tapered if there are signs of aGVHD or if cGVHD exceeding mild skin disease develops. If GVHD develops, the higher target level (ie, 200 to 300 mg/mL) is maintained.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MSD graft</strong> – For an MSD graft, if the patient has no evidence of GVHD, CsA may be tapered at approximately day +90 and discontinued by the end of six months. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other graft donors</strong> – For MUD grafts or mismatched related donor grafts, CsA may need to be continued for longer, sometimes even for years. </p><p></p><p class="bulletIndent1">It is important to monitor patients carefully for development of cGVHD during the taper; the onset of cGVHD can be fulminant at times. The same concern applies to patients who receive <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (either as a component of the prophylaxis regimen or for the treatment of aGVHD). (See  <a class="medical medical_review" href="/z/d/html/3548.html" rel="external">"Clinical manifestations and diagnosis of chronic graft-versus-host disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects (AEs)</strong> – The major clinical toxicities of CsA are renal insufficiency and elevated bilirubin levels; both AEs are dose-related. </p><p></p><p class="bulletIndent1">CsA is highly lipophilic and it is extensively metabolized with subsequent biliary excretion; there is limited urinary excretion. Some of the &gt;15 metabolites of CsA have immunosuppressive activity, while others are nephrotoxic. The clinical efficacy and interactions between CsA and other drugs may be confounded by its metabolites. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Kidney</strong> – Acute nephrotoxicity is due to vasoconstriction and ischemia of the afferent arterioles in the kidney [<a href="#rid36">36</a>]. These acute changes are reversible, but they can lead to irreversible interstitial injury with glomerular thrombosis, causing permanent azotemia. It is important to distinguish CsA-associated nephrotoxicity from AEs of other drugs (eg, amphotericin, MTX, aminoglycosides) and from GVHD, itself. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver</strong> – Cytochrome p450 IIIA enzymes (eg, HLp and PCN1) can inhibit or induce CsA metabolism. This interaction is important to keep in mind, especially when patients are treated with antifungal medications (eg, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>), which may significantly increase CsA levels. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurotoxicity</strong> – CsA can cause neurotoxicity, which may be more prominent with concomitant hypomagnesemia or hypocholesterolemia. Neurologic AEs can involve all levels of the neuraxis, including cortical blindness. Associated abnormalities include elevated cerebrospinal fluid protein and pleocytosis, electroencephalographic abnormalities, and central and extrapontine myelinolysis with imaging. In most patients, these events were reversible with dose reduction or withdrawal of CsA.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other AEs</strong> – Other AEs include hypertension, hyperglycemia, headaches, and hirsutism. Rarely, gum hypertrophy, brittle nails, acne, nausea, and vomiting develop. </p><p></p><p class="bulletIndent2">Calcium channel blockers are the drugs of choice if hypertension develops. However, some such agents (eg, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>) can affect CsA levels, which may require adjusting the CsA dose. (See  <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus", section on 'Side effects'</a>.)</p><p></p><p class="headingAnchor" id="H786782665"><span class="h3">Tacrolimus (Tac)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> (FK506) is a highly lipophilic macrolide that was originally extracted from a soil fungus. It is structurally distinct from CsA, which is a cyclic peptide, but its mechanism of action (immunosuppression through inhibition of signaling via the T cell receptor) and efficacy are similar to CsA. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Prophylaxis is initiated with Tac at 0.03 to 0.04 mg/kg/day by continuous infusion. The target trough range for Tac is 15 ng/mL. <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> can leach into plastic catheters, so it is important that the lumen used to measure serum levels is separate from the lumen through which tacrolimus is infused; otherwise serum levels are likely to be falsely elevated. </p><p></p><p class="bulletIndent1">Tac administration can be converted to the oral route (0.15 mg/kg/day, in two divided doses) when eating and drinking occur without significant difficulties.</p><p></p><p class="bulletIndent1">Tac is almost completely metabolized in the liver (through demethylation and hydroxylation) prior to its elimination. The half-life is approximately nine hours, but it is longer in patients with liver dysfunction. GI absorption of Tac does not seem to depend on the presence of bile salts, which distinguishes it from CsA. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Tac can cause neurotoxicity, renal toxicity, hyperkalemia, and hyperglycemia. The AEs are similar to those associated with CsA, but there is less hypertension associated with Tac [<a href="#rid37">37</a>]. Hypertension should be managed with calcium channel blockers (as described for CsA above). (See <a class="local">'Cyclosporine (CsA)'</a> above.)</p><p></p><p class="bulletIndent1">Central nervous system (CNS) effects can occur, including headaches, tremors, paresthesias, photophobia, mental status changes, and coma [<a href="#rid38">38</a>]. Other AEs include dyspnea, musculoskeletal pain, itching, GI complaints (eg, anorexia, nausea, vomiting, abdominal pains), and fatigue. </p><p></p><p class="bulletIndent1">Tac has also been associated with TMA. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)", section on 'Immunosuppressive agents'</a>.)</p><p></p><p class="headingAnchor" id="H3662561916"><span class="h1">ANTIMETABOLITES</span></p><p class="headingAnchor" id="H2744365741"><span class="h2">Choice of antimetabolite</span><span class="headingEndMark"> — </span>The choice of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) versus <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) as an antimetabolite varies with the conditioning regimen, risk factors for GVHD, and institutional preference. </p><p>MTX and MMF are generally associated with similar survival outcomes, but MTX is associated with less acute GVHD (aGVHD), while MMF is associated with faster engraftment and less mucositis, as described above. (See <a class="local">'Conditioning regimen'</a> above and <a class="local">'Other considerations'</a> above.)</p><p class="headingAnchor" id="H3714061859"><span class="h3">Methotrexate (MTX)</span><span class="headingEndMark"> — </span>MTX inhibits dihydrofolate reductase (DHFR), the intracellular enzyme that converts <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> to tetrahydrofolates, which are responsible for transport of single carbon groups needed for purine and thymidylate synthesis. MTX induces immune tolerance by blocking proliferation of activated T cells.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – Patients with a known third-space fluid collection (eg, ascites, pleural effusions) should <strong>not</strong> receive MTX. The MTX dose is usually reduced in patients who have hyperbilirubinemia, severe mucositis, or renal insufficiency; care should be exercised to avoid other factors that might predispose to severe MTX toxicity.  </p><p></p><p class="bulletIndent1">Patients should be well hydrated and have their urine alkalinized with <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> to aid MTX excretion and minimize its precipitation in renal tubules, which can lead to acute renal failure. This can be achieved by the administration of roughly 3 liters per day of dextrose in water to which 44 to 66 mEq of sodium bicarbonate has been added. MTX should not be administered until the urine pH is ≥8.0. </p><p></p><p class="bulletIndent1">Ascites and pleural effusions can accumulate high levels of MTX that slowly leach into the circulation long after the initial dose; this can result in prolonged drug elimination and severe delayed toxicity, particularly if renal function is impaired. MMF can be considered as an alternative antimetabolite for patients with impaired kidney function or fluid collections. (See <a class="local">'Mycophenolate mofetil (MMF)'</a> below.)</p><p></p><p class="bulletIndent1">Prevention and management of MTX toxicity is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Prevention and management of high-dose methotrexate toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial dose</strong> – The first dose of MTX is 15 mg/m<sup>2</sup>, given intravenously on day +1, followed 24 hours later by <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a> rescue (15 mg orally every six hours for three doses)  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>); leucovorin can be given intravenously, instead of orally, if there is severe mucositis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent doses</strong> – Three additional doses of MTX (10 mg/m<sup>2</sup>) are given on days +3, +6 and +11. <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">Leucovorin</a> rescue is given (15 mg orally every six hours for four doses) after each dose of MTX. Full target doses of MTX may not be achievable in patients who already have grade 3-4 mucositis (eg, from the conditioning regimen). The day +11 dose should be decreased or omitted in case of any grade ≥2 adverse effects (AEs). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most common AEs when MTX is used for GVHD prophylaxis are renal, hepatic, and gastrointestinal toxicity (especially severe mucositis), delayed hematopoietic recovery, and organ toxicity [<a href="#rid31">31,39-41</a>].</p><p></p><p class="bulletIndent1">Patients commonly have an elevation in creatinine and bilirubin levels following MTX administration. As these are also the AEs associated with CNIs, dose attenuation of MTX, Tac, or CsA may be necessary. (See  <a class="medical medical_review" href="/z/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a> and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a> and  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Common toxicities'</a>.)</p><p></p><p class="headingAnchor" id="H4620890"><span class="h3">Mycophenolate mofetil (MMF)</span><span class="headingEndMark"> — </span>MMF is an ester prodrug of mycophenolic acid and a known inhibitor of inosine monophosphate dehydrogenase. MMF selectively inhibits de novo purine biosynthesis in activated lymphocytes; it has less effect on neutrophils and this selectivity seems to spare the higher risk of acute infections.</p><p>MMF is generally used for non-myeloablative conditioning (MAC) hematopoietic cell transplantation (HCT), for patients receiving MAC with a contraindication to MTX (eg, fluid collection), or for patients who need rapid engraftment (eg, those with aspergillosis) [<a href="#rid42">42</a>]. (See <a class="local">'Non-MAC regimens'</a> above and <a class="local">'Other considerations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – MMF dose is 1 gram orally twice daily, beginning on day +1; the dose can be increased to 1 gram three times daily [<a href="#rid43">43</a>]. MMF dose should be adjusted according to toxicity.</p><p></p><p class="bulletIndent1">For children, the MMF dose is 30 mg/kg/day, given orally in two doses  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Matched sibling donor (MSD) grafts</strong> – For MSD grafts, MMF prophylaxis is for one month.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other donor grafts</strong> – For other donor sources, (eg, mismatched sibling or unrelated donors), MMF is given for three months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Hematologic AEs (primarily neutropenia) are the most common toxicity, but gastrointestinal AEs are reported occasionally. Doses up to 1.5 gram twice daily had no nephrotoxicity, myelosuppression, or other serious side effects in patients with rheumatoid arthritis. (See  <a class="medical medical_review" href="/z/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Mycophenolate mofetil'</a>.)</p><p></p><p class="bulletIndent1">Rarely, MMF has rarely been associated with progressive multifocal leukoencephalopathy (PML) and opportunistic infections. (See  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1596139051"><span class="h1">T CELL DEPLETION (TCD)</span><span class="headingEndMark"> — </span>TCD can be via in vivo or ex vivo methods.</p><p class="headingAnchor" id="H263518593"><span class="h2">In vivo TCD</span></p><p class="headingAnchor" id="H2953887089"><span class="h3">Antithymocyte globulin (ATG)</span><span class="headingEndMark"> — </span>ATG is a polyclonal immune globulin prepared by injecting various cellular preparations into animals. ATG has been used as a component of transplant conditioning regimen (to decrease the incidence of graft rejection) or after allogeneic hematopoietic cell transplantation (HCT) to ameliorate GVHD, especially for graft sources that are associated with increased risk for GVHD (eg, unrelated donors, haploidentical grafts). (See <a class="local">'Matched unrelated donor (MUD)'</a> above and <a class="local">'Haploidentical donor'</a> above.)</p><p><a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">Rabbit antithymocyte globulin</a> (rATG) is the preferred product for GVHD prophylaxis. It is more efficacious than <a class="drug drug_general" data-topicid="9107" href="/z/d/drug information/9107.html" rel="external">horse antithymocyte globulin</a> (hATG) and there is less lot-to-lot variation in potency. Use of ATG as a component of GVHD prophylaxis does not confer a survival advantage; it is associated with less acute GVHD (aGVHD) and less need for other medications to control GVHD, but it is associated with an increased risk for post-transplant lymphoproliferative disorders (PTLD).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – The recommended dose of rATG is dose is 15 mg/kg [<a href="#rid44">44</a>]. While the measurable half-life of the antibody is approximately nine hours, the functional half-life is not known. </p><p></p><p class="bulletIndent1">Corticosteroids, <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, H1 and H2 blockers are frequently used to prevent or treat the symptoms associated with the infusion of ATG. (See  <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease", section on 'Anti-thymocyte globulin (ATG)'</a>.)</p><p></p><p class="bulletIndent1">If hATG is used, doses are generally in the range of 10 to 30 mg/kg per day. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Since ATG is both a foreign xenogeneic protein and an antibody, serum sickness can occur after its use. Diagnosis and management of serum sickness are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2078.html" rel="external">"Serum sickness and serum sickness-like reactions"</a>.) </p><p></p><p class="bulletIndent1">The use of ATG after HCT has been associated with an increase in PTLD [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/7335.html" rel="external">"Treatment and prevention of post-transplant lymphoproliferative disorders"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Addition of ATG to standard prophylaxis is associated with similar survival and less chronic GVHD (cGVHD) but an increased risk for viral reactivation, as described above. (See <a class="local">'Matched unrelated donor (MUD)'</a> above.) </p><p></p><p class="headingAnchor" id="H1422605176"><span class="h3">Post-transplant cyclophosphamide (PTCy)</span><span class="headingEndMark"> — </span>PTCy can lower the incidence of both aGVHD and cGVHD after allogeneic HCT. The mechanism of action is not certain, but PTCy may deplete or suppress alloreactive T cells in the host and/or support development of regulatory T cell (Treg)-mediated tolerance [<a href="#rid46">46,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/96032.html" rel="external">"HLA-haploidentical hematopoietic cell transplantation"</a>.)</p><p>PTCy is a standard approach for haploidentical (haplo) HCT, but it also has been used for matched sibling donor (MSD) and unrelated donor grafts [<a href="#rid48">48,49</a>]. It is administered after infusion of the graft to remove alloreactive T cells and stimulate Treg recovery [<a href="#rid23">23</a>]. PTCy can induce immune tolerance without causing global myelosuppression, because hematopoietic stem cells express high levels of aldehyde dehydrogenase (ALDH), which confers cellular resistance to <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (Cy) [<a href="#rid50">50</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – PTCy uses a brief course of high-dose Cy (50 mg/kg per day on days +3 and +4) as a single agent or together with <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (Tac) or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (CsA). </p><p></p><p class="bulletIndent1">Cy is not currently approved by the US Food and Drug Administration (FDA) for GVHD prophylaxis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – Adverse effects (AEs) are related to myelosuppression, nausea/vomiting, and hemorrhagic cystitis. Pulmonary injury is rare,<sup> </sup>but it can present with early acute pneumonitis or chronic progressive pulmonary fibrosis. Cardiotoxicity may include myocarditis, arrhythmias, and/or congestive heart failure. Cy can cause secondary malignancies and embryo-fetal toxicity. (See  <a class="medical medical_review" href="/z/d/html/2812.html" rel="external">"Cardiotoxicity of cancer chemotherapy agents other than anthracyclines, HER2-targeted agents, and fluoropyrimidines", section on 'Cyclophosphamide'</a>.)</p><p></p><p class="bulletIndent1">When used in high doses, Cy metabolites can cause hemorrhagic cystitis. (See  <a class="medical medical_review" href="/z/d/html/2829.html" rel="external">"Chemotherapy and radiation-related hemorrhagic cystitis in cancer patients", section on 'Cyclophosphamide'</a>.)</p><p></p><p class="bulletIndent1">Drugs that alter cytochrome P450 (eg, alcohol, barbiturates, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>) may accelerate metabolism of Cy into its active metabolites, increasing both pharmacologic and toxic effects of the drug. Conversely, drugs that inhibit cytochrome P450 (eg, corticosteroids, <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, tricyclic antidepressants) may slow conversion of Cy into its metabolites and consequently reduce therapeutic and toxic effects. </p><p></p><p class="bulletIndent1">Cy is metabolized, primarily in the liver, to 4-OH Cy, acrolein, and the active component, phosphoramide mustard, which forms irreversible intra- and inter-strand cross-linkages at guanine N-7 positions in DNA and leads to apoptosis [<a href="#rid51">51</a>]. Many tissues, including bone marrow, liver, and intestinal epithelium have abundant ALDH, which lessens toxicity on these organs. Cy metabolites are primarily excreted unchanged in the urine; drug dosing should be adjusted in the setting of renal dysfunction [<a href="#rid52">52</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Studies of PTCy for haploidentical (haplo) HCT are presented above. (See <a class="local">'Haploidentical donor'</a> above.)</p><p></p><p class="bulletIndent1">PTCy has also been examined for non-haplo graft sources:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multicenter randomized phase 2 study reported that for reduced intensity conditioning (RIC) HCT, patients who received PTCy had superior GVHD-free/relapse-free survival (GRFS) compared with other GVHD prophylaxis regimens [<a href="#rid33">33</a>]. (See <a class="local">'Non-MAC regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A retrospective study of PTCy for matched unrelated donors (MUD) reported 60 percent two-year overall survival (OS), 56 percent leukemia-free survival (LFS), 16 to 20 percent nonrelapse mortality (NRM), and relapse in approximately one-quarter of patients [<a href="#rid53">53</a>]. Day 100 grade 2-4 and grade 3-4 aGVHD were 28 percent and 10 percent, respectively, and extensive cGVHD was 21 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Preliminary results of a phase 3 trial, reported in abstract form, found that PTCy was associated with improved GRFS compared with conventional immunosuppression (CsA plus MMF) for MSD or MUD grafts [<a href="#rid54">54</a>]. </p><p></p><p>Other studies describe PTCy as safe and effective for preventing graft rejection and reducing aGVHD and cGVHD following myeloablative or nonmyeloablative conditioning with T cell-replete grafts from partially mismatched related donors [<a href="#rid23">23,24,55-58</a>]. </p><p class="headingAnchor" id="H294876732"><span class="h2">Ex vivo TCD</span><span class="headingEndMark"> — </span>Eliminating T lymphocytes ex vivo could reduce the incidence of GVHD. Most such methods have been associated with no improvement in OS, but they may increase graft failure and disease relapse and delay immune reconstitution. There is no standard approach, and use of ex vivo TCD varies among institutions.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methods</strong> – Methods to deplete T lymphocytes from donor bone marrow include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ex-vivo treatment of the donor bone marrow with monoclonal antibodies with broad reactivity (eg, anti-CD52, anti-CD2, anti-CD3, and anti-CD5 antibodies) or more restricted reactivity (eg, anti-CD8 and anti-CD25).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical separation techniques include density gradients, selective depletion with lectins, treatment with cytotoxic drugs, and the use of anti-T cell sera or monoclonal antibodies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – In studies comparing TCD with pharmacologic therapy for the prevention of GVHD, TCD was associated with lower rates of severe aGVHD but higher rates of graft failure, relapse, infections, and other complications. </p><p></p><p class="bulletIndent1">As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A multicenter phase 3 trial compared TCD (using two different methods) plus CsA versus CsA/MTX in &gt;400 patients receiving unrelated donor bone marrow HCT for hematologic malignancies [<a href="#rid59">59,60</a>]. TCD was associated with less grade 3-4 aGVHD (18 versus 37 percent), but no significant difference in cGVHD (29 versus 34 percent), transplant-related mortality (TRM), or three-year disease-free survival (DFS). Patients TCD grafts had a higher risk of relapse (20 versus 9 percent) and a higher risk of cytomegalovirus infection (28 versus 17 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter phase 2 study, ex vivo CD34+ cell selection was the sole method of GVHD prophylaxis in 44 patients undergoing MSD HCT for acute myeloid leukemia (AML) in first or second remission [<a href="#rid61">61</a>]. When compared with a similar population of 84 patients receiving T cell-replete grafts and treated with calcineurin inhibitor (CNI)-based GVHD prophylaxis, TCD was associated with similar rates of grade 2-4 aGVHD (23 versus 39 percent), lower rates of cGVHD (19 versus 50 percent), and a lower percentage of patients requiring immunosuppression at one year (12 versus 54 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Depletion of naïve T cells from human leukocyte antigen (HLA)-matched peripheral blood (PB) graft sources was associated with infrequent, mild GVHD in a study of 138 patients who received myeloablative conditioning (MAC) HCT [<a href="#rid62">62</a>]. Donors were treated with granulocyte colony-stimulating factor (G-CSF) for five days and positive selection of CD34+ progenitor cells was followed by depletion of CD45RA+ cells from the CD34-negative fraction. Grade 3 and grade 4 aGVHD were reported in 4 percent and 0 percent of patients, respectively; only two patients required treatment beyond corticosteroids. Three-year cumulative incidence of mild, moderate, and severe cGVHD were 6, 1, and 0 percent, respectively. Other outcomes at three years included OS (77 percent), relapse-free survival (69 percent), and 64 percent GRFS.</p><p></p><p class="headingAnchor" id="H1233113674"><span class="h1">OTHER TREATMENTS</span></p><p class="headingAnchor" id="H1529225908"><span class="h2">Abatacept</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a> is a selective inhibitor of T cell costimulation that may reduce acute GVHD (aGVHD) when added to a calcineurin inhibitor (CNI) plus <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX). </p><p>A phase 2 study reported that adding <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> to a CNI/MTX was associated with less aGVHD compared with a CNI/MTX [<a href="#rid63">63</a>]. The study included two strata: a randomized, double-blind, placebo-controlled cohort of 8/8 human leukocyte antigen (HLA)-matched unrelated donors (MUD) and a second cohort in which patients with 7/8 HLA-allele MUD grafts who received abatacept plus a CNI/MTX were compared with historical control patients treated with a CNI/MTX: </p><p class="bulletIndent1"><span class="glyph">●</span>In the 8/8 HLA-matched cohort, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>/CNI/MTX was associated with a lower incidence of day 100 grade 2-4 aGVHD (43 versus 62 percent; HR 0.53 [95% CI 0.39-0.71]), but there was no difference in two-year overall survival (OS), relapse-free survival (RFS), nonrelapse mortality (NRM), grade 3-4 aGVHD, or chronic GVHD (cGVHD), compared with patients randomly assigned to CNI/MTX (no abatacept). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the 7/8 HLA-matched cohort, <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> was associated with improved two-year OS (74 to 77 percent versus 45 percent; HR 0.28 [95% CI 0.16-0.48]), superior two-year NRM and RFS, less grade 2-4 aGVHD at day 100 and day 180, but no difference in cGVHD, compared with historical controls.</p><p></p><p>An ongoing multicenter phase 2 study (#NCT03924401) is evaluating <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> for prevention of cGVHD.</p><p><a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">Abatacept</a> is the first drug approved by the US Food and Drug Administration (FDA) for aGVHD prophylaxis.</p><p class="headingAnchor" id="H4074674920"><span class="h2">Antibiotics (to alter gut flora)</span><span class="headingEndMark"> — </span>Observational studies suggest that the diversity and composition of intestinal bacteria (ie, gastrointestinal [GI] microbiome) plays a role in the development of GVHD involving the lower GI tract. GI GVHD has been associated with the expansion of certain pro-inflammatory bacteria (eg, <em>Enterobacteriaceae</em>), a decrease in anti-inflammatory bacteria (eg, <em>Clostridia spp.</em>), and less bacterial diversity overall [<a href="#rid64">64-67</a>]. </p><p>An international study of &gt;1300 patients reported that alterations of the intestinal microbiome were associated with increased mortality from GVHD [<a href="#rid68">68</a>]. Loss of bacterial diversity and domination by single taxa before and after transplantation were independently associated with increased GVHD-associated mortality and transplantation-related mortality (TRM). It is not clear at present if this association reflects a causal relationship or if the microbiome can be manipulated to influence outcomes. (See  <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">"Pathogenesis of graft-versus-host disease (GVHD)", section on 'Microbiome'</a>.)</p><p>In a phase 3 trial, 134 patients undergoing allogeneic HCT were randomly assigned to receive either <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> or ciprofloxacin plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for five weeks following transplantation [<a href="#rid69">69</a>]. There was no difference in five-year OS or incidence of cGVHD, but among patients who received matched sibling donor (MSD) grafts, combination antibiotic treatment was associated with less grade 2-4 aGVHD (18 percent compared with 54 percent with ciprofloxacin alone). The incidence of aGVHD did not differ for recipients of partially matched related or unrelated grafts (36 versus 46 percent). </p><p>Some experts begin an antibiotic (eg, a quinolone) on the day before initiating the conditioning regimen and continue it until patients have engrafted or are started on intravenous antibiotics. (See  <a class="medical medical_review" href="/z/d/html/1397.html" rel="external">"Prevention of infections in hematopoietic cell transplant recipients", section on 'Antibacterial prophylaxis'</a>.)</p><p class="headingAnchor" id="H643013606"><span class="h2">Prednisone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> is used for treatment of aGVHD, but it is not part of standard prophylactic regimens because of the toxicity of long-term treatment. </p><p><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> can be used if there are concerns about administering MTX or in patients at high risk of hepatic sinusoidal obstructive syndrome (SOS; also called veno-occlusive disease)  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease"</a> and  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Risk factors'</a>.)</p><p>Prospective trials have evaluated the use of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> in combination with other agents (eg, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> [CsA], MTX, or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) for the prevention of GVHD [<a href="#rid70">70-78</a>]. While a meta-analysis suggested that the addition of glucocorticoids significantly reduced the risk of both mild and severe aGVHD, there were no alterations in OS, disease-free survival (DFS), or the incidence of relapse [<a href="#rid79">79</a>].</p><p>Long-term follow-up (median &gt;24 years) from one phase 3 trial reported that, compared with patients who received CsA plus MTX, patients who received <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> plus CsA and MTX had superior OS (55 versus 20 percent, respectively) and RFS (49 versus 15 percent) [<a href="#rid78">78</a>]. There was more late nonrecurrence mortality in the group not given methylprednisolone (11 versus 0 deaths &gt;15 years after transplantation), but no differences in rates of disease recurrence or secondary malignancies.</p><p class="headingAnchor" id="H1843968997"><span class="h2">Rituximab</span><span class="headingEndMark"> — </span>There is no demonstrated role for <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> (CD20-directed monoclonal antibody) as prophylaxis against GVHD.</p><p>Addition of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> to standard GVHD prophylaxis was associated with no improvement in OS or grade 2-4 GVHD in a randomized open-label phase 2 study that included 84 patients with aggressive lymphomas [<a href="#rid80">80</a>].</p><p class="headingAnchor" id="H1307428052"><span class="h2">Sirolimus</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> (Sir; also called rapamycin) is a lipophilic macrolide isolated from a soil sample from Easter Island (Rapa Nui). </p><p>Sir is not currently approved by the US FDA for use against GVHD.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – The major effect of Sir is to interfere with the CD28 signaling pathway. Secondary signals required for T cell activation and proliferation depend on ligation of the B7 family with CD28; an absence of the secondary signal results in T cell anergy. Sir inhibits progression of cells from G1 into the S phase and interrupts signal transduction pathways that mediate specific cytokine responses (eg, interleukin [IL]-1-driven interferon-gamma production) [<a href="#rid81">81,82</a>]. </p><p></p><p class="bulletIndent1">Sir binds to the same family of intracellular receptors as <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (Tac; ie, FK-binding proteins [FKBP]), but the two drugs have distinct mechanisms of action; Tac (and CsA) inhibit T cell proliferation by altering signaling downstream of the T cell receptor (TCR). (See <a class="local">'Calcineurin inhibitors (CNI)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Sir is administered orally and monitored twice weekly to maintain a target plasma level of 8 to 14 ng/mL for the first two months and 5 to 8 ng/mL until discontinuation. Sir has been combined with Tac or with post-transplant <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (PTCy) and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF) as non-MTX-containing regimens (eg, to avoid mucositis) [<a href="#rid83">83,84</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects (AEs)</strong> – Elevated liver function tests, diarrhea, hypertriglyceridemia, and cytopenias are the most common AEs; blood pressure changes, headaches, nausea, mucous membrane irritation, and infections also occur. Nephrotoxicity is rarely encountered with Sir, although it may potentiate the nephrotoxicity of CsA. </p><p></p><p class="bulletIndent1">Sir has been associated with hepatic SOS following myeloablative conditioning (MAC) regimens, especially when myeloablative doses of <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a> were employed [<a href="#rid85">85</a>]. Myeloablative doses of busulfan should <strong>not</strong> be used with sirolimus-based immunosuppression [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– Sir has been evaluated in several settings: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MSD grafts</strong> – A phase 3 trial in 304 patients undergoing MSD HCT reported that Tac plus Sir versus Tac plus MTX were associated with similar survival and incidence of GVHD, but Sir was associated with faster engraftment and less mucositis [<a href="#rid83">83</a>]. Compared with Tac/MTX, Tac/Sir was associated with similar two-year OS (59 versus 63 percent) and RFS (53 versus 54 percent) and similar rates of grade 2-4 aGVHD (26 versus 34 percent) and cGVHD (53 versus 45 percent). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Haploidentical HCT</strong> – Sir-based GVHD prophylaxis (using PTCy and MMF; ie, a CNI-free regimen) for haploidentical MAC HCT was associated with a low rate of GVHD, a high rate of engraftment, acceptable rates of NRM and GVHD, but a high incidence of viral reactivation (eg, CMV, EBV, HHV6) and other infections [<a href="#rid84">84</a>]. Among the 40 patients, one-year OS and DFS were 56 and 48 percent, respectively, one-year NRM was 17 percent, and 35 percent relapsed. There were no cases of hepatic SOS or thrombotic microangiopathy (TMA), but one case of posterior reversible encephalopathy syndrome (PRES).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Peripheral blood (PB) grafts</strong> – <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> plus Tac (ie, without MTX) for GVHD prophylaxis in PB MAC HCT was associated with rapid engraftment, a low incidence of aGVHD, minimal transplant-related toxicity, and good survival; hepatic SOS occurred in 8 percent of patients [<a href="#rid87">87</a>]. At day 100, TRM was 5 percent; transplant-related complications included seven patients with hepatic SOS (four died of this complication) and TMA in six patients. Outcomes were similar for recipients of MSD and unrelated donor grafts, and included 72 percent two-year OS, 68 percent two-year RFS, 21 percent grade 2-4 aGVHD, 5 percent grade 3-4 aGVHD, and 59 percent cGVHD. Day 30 TRM was 0 percent and day 100 TRM was 5 percent. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>HCT for lymphomas</strong> – In a retrospective study of 190 patients, compared with a CNI plus MTX, treatment that included Sir was associated with improved OS and decreased risk of disease progression in lymphoma patients undergoing allogeneic HCT [<a href="#rid88">88</a>]. The benefit was restricted to patients undergoing reduced intensity conditioning (RIC) HCT: 66 percent three-year OS compared with 38 percent for non-Sir group. Patients who received Sir had a similar incidence of NRM but decreased incidence of disease progression (42 versus 74 percent). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children</strong> – A phase 3 trial in 146 children reported that addition of Sir to Tac/MTX was associated with no difference in two-year OS, event-free survival (EFS), or grade 3-4 aGVHD, less grade 2-4 aGVHD (18 versus 31 percent), but more treatment-related complications [<a href="#rid89">89</a>]. Grafts included MSD, MUD, and umbilical cord blood (UCB) donors. Compared with Tac/MTX, there was more hepatic SOS in patients receiving Tac/MTX/Sir (21 percent versus 9 percent) and more TMA (10 versus 1 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence of hepatic SOS</strong> – A retrospective review of 488 patients reported that Sir was associated with an increased incidence of hepatic SOS (16 versus 7 percent for patients who did not receive Sir) [<a href="#rid85">85</a>]. Rates of SOS varied according to the prophylaxis regimen: Tac/MTX (7 percent), Tac/Sir (11 percent), and Tac/Sir/MTX (21 percent). Compared with Tac/MTX, the odds ratio (OR) for hepatic SOS with Tac/Sir/MTX was 3.23 [95% CI 1.61-6.69]). Death occurred in at least one-third of SOS-affected patients. Use of an unrelated or mismatched donor further increased the risk of SOS. When combined with busulfan-based conditioning, the risk of SOS was still higher (OR 8.8). </p><p></p><p class="bulletIndent1">Diagnosis and management of hepatic SOS in adults and children are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a> and  <a class="medical medical_review" href="/z/d/html/129810.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in children"</a>.)</p><p></p><p class="headingAnchor" id="H2635051167"><span class="h2">Sitagliptin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">Sitagliptin</a>, which is approved for treatment of type 2 diabetes mellitus, is an inhibitor of T cell costimulation that may be effective against aGVHD in combination with Tac and Sir. Sitagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4; also known as CD26), a homodimeric transmembrane receptor expressed on T cells. DPP-4 interacts with caveolin on antigen-presenting cells (APC), which upregulates CD86 on APCs and results in costimulation [<a href="#rid90">90,91</a>]. </p><p>In a phase 2 study of 36 patients who underwent myeloablative allogeneic HCT, <a class="drug drug_general" data-topicid="9482" href="/z/d/drug information/9482.html" rel="external">sitagliptin</a> in combination with Tac/Sir was associated with 5 percent day 100 grade 2-4 aGVHD [<a href="#rid92">92</a>]. At one year, 46 percent of patients were GVHD-free/relapse-free and no toxic effects were attributed to sitagliptin. Compared with previous studies using Tac/Sir, addition of sitagliptin was associated with decreased GVHD but no increase in relapses, suggesting no loss of graft-versus-leukemia effect. Sitagliptin was previously shown to be safe and effective in reducing aGVHD after UCB transplantation [<a href="#rid93">93,94</a>].</p><p class="headingAnchor" id="H3794687878"><span class="h2">Tocilizumab</span><span class="headingEndMark"> — </span>There is no proven benefit for adding <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (Toci), an inhibitor of interleukin-6 (IL-6), to standard GVHD prophylaxis. Involvement of IL-6 in the pathogenesis of aGVHD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">"Pathogenesis of graft-versus-host disease (GVHD)"</a>.) </p><p>In a phase 3 trial, addition of Toci to MTX and CsA did not alter median survival, but it was associated with trends toward less aGVHD and improved GVHD-free survival, with little incremental toxicity [<a href="#rid95">95</a>]. In this multicenter trial, 145 patients were treated with CsA/MTX plus either Toci (8 mg/kg to a maximum 800 mg as a single intravenous infusion over 60 minutes) or placebo on day -1. Compared with placebo, Toci was associated with a lower incidence of grade 2-4 aGVHD at day 100 (36 versus 27 percent) and at day 180 (40 versus 29 percent), but neither difference was statistically significant. There were similar levels of liver toxicity and infectious complications in both trial arms. </p><p>Single-arm prospective studies had also suggested that Toci was associated with a reduced incidence of GVHD, compared with historical controls [<a href="#rid96">96,97</a>]. </p><p class="headingAnchor" id="H3313973940"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft-versus-host disease (GVHD)</strong> – GVHD occurs when immune cells transplanted from a nonidentical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction in the recipient. The pathogenesis of GVHD is a complex, multistep process, but it is primarily initiated by T lymphocytes. (See  <a class="medical medical_review" href="/z/d/html/3545.html" rel="external">"Pathogenesis of graft-versus-host disease (GVHD)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppressive backbone</strong> – For GVHD prophylaxis in allogeneic hematopoietic cell transplantation (HCT), we suggest a calcineurin inhibitor (CNI) <strong>plus</strong> an antimetabolite, rather than a CNI alone or an antimetabolite alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). CNIs include <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> (Tac) or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (CsA), while antimetabolites include either <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (MTX) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil (MMF)  (<a class="graphic graphic_table graphicRef91020" href="/z/d/graphic/91020.html" rel="external">table 1</a>). (See <a class="local">'Immunosuppressive backbone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selection of a GVHD prophylactic regimen varies according to the degree of immunologic match, transplant conditioning regimen, graft source (ie, bone marrow versus peripheral blood), and other risk factors: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Matched sibling donor (MSD) graft</strong> – For HCT with a human leukocyte antigen (HLA)-matched sibling/related donor, we suggest use of CNI plus MTX rather than CNI plus MMF (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Matched sibling donor (MSD)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Matched unrelated donor (MUD) graft</strong> – For HCT using an MUD (ie, ≥9/10 or ≥7/8 HLA alleles), we suggest the addition of antithymocyte globulin (ATG) to a CNI plus MTX, rather than other regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Matched unrelated donor (MUD)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Haploidentical (haplo) HCT </strong>– For haplo HCT, we suggest adding post-transplant <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (PTCy) to a CNI plus MMF, rather than other immunosuppressive regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Haploidentical donor'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Myeloablative conditioning (MAC)</strong> – For MAC allogeneic HCT, we suggest a CNI plus MTX, rather than a CNI plus MMF (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Myeloablative conditioning (MAC)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Non-MAC</strong> – For adults undergoing nonmyeloablative conditioning (NMA) or reduced intensity conditioning (RIC) allogeneic HCT, we suggest a CNI plus MMF, rather than a CNI plus MTX (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Non-MAC regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Peripheral blood stem/progenitor cell (PBSPC) grafts</strong> – For transplantation using a peripheral blood graft source, we consider treatment with either CNI (Tac or CsA) plus either MTX or MMF acceptable. (See <a class="local">'Peripheral blood grafts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of a CNI</strong> – Tac and CsA are structurally distinct, but they have similar clinical properties, efficacy, and toxicity. Selection of a CNI for GVHD prophylaxis is largely guided by institutional preference. (See <a class="local">'Choice of CNI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of an antimetabolite</strong> – The choice of MTX versus MMF varies with the conditioning regimen, patient factors, and institutional preference. (See <a class="local">'Conditioning regimen'</a> above and <a class="local">'Other considerations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21:389.</a></li><li><a class="nounderline abstract_t">Ruutu T, van Biezen A, Hertenstein B, et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47:1459.</a></li><li><a class="nounderline abstract_t">Penack O, Marchetti M, Ruutu T, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7:e157.</a></li><li><a class="nounderline abstract_t">Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729.</a></li><li><a class="nounderline abstract_t">Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68:119.</a></li><li><a class="nounderline abstract_t">Storb R, Deeg HJ, Pepe M, et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989; 72:567.</a></li><li><a class="nounderline abstract_t">Ringdén O, Klaesson S, Sundberg B, et al. Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. Bone Marrow Transplant 1992; 9:19.</a></li><li><a class="nounderline abstract_t">Mrsić M, Labar B, Bogdanić V, et al. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1990; 6:137.</a></li><li><a class="nounderline abstract_t">Gluckman E, Horowitz MM, Champlin RE, et al. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79:269.</a></li><li><a class="nounderline abstract_t">Storb R, Deeg HJ, Whitehead J, et al. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. Transplant Proc 1987; 19:2608.</a></li><li><a class="nounderline abstract_t">Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96:2062.</a></li><li><a class="nounderline abstract_t">Inamoto Y, Flowers ME, Appelbaum FR, et al. A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. Biol Blood Marrow Transplant 2011; 17:1088.</a></li><li><a class="nounderline abstract_t">Kanda Y, Kobayashi T, Mori T, et al. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant 2016; 51:103.</a></li><li><a class="nounderline abstract_t">Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303.</a></li><li><a class="nounderline abstract_t">Arai Y, Jo T, Matsui H, et al. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma 2017; 58:1840.</a></li><li><a class="nounderline abstract_t">Theurich S, Fischmann H, Shimabukuro-Vornhagen A, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev 2012; :CD009159.</a></li><li><a class="nounderline abstract_t">Kröger N, Solano C, Wolschke C, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med 2016; 374:43.</a></li><li><a class="nounderline abstract_t">Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 2016; 17:164.</a></li><li><a class="nounderline abstract_t">Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10:855.</a></li><li><a class="nounderline abstract_t">Finke J, Schmoor C, Bethge WA, et al. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol 2017; 4:e293.</a></li><li><a class="nounderline abstract_t">Ruggeri A, Sun Y, Labopin M, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica 2017; 102:401.</a></li><li><a class="nounderline abstract_t">Kasamon YL, Bolaños-Meade J, Prince GT, et al. Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol 2015; 33:3152.</a></li><li><a class="nounderline abstract_t">Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14:641.</a></li><li><a class="nounderline abstract_t">Kanakry CG, O'Donnell PV, Furlong T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 2014; 32:3497.</a></li><li><a class="nounderline abstract_t">Solomon SR, Sizemore CA, Sanacore M, et al. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transplant 2015; 21:1299.</a></li><li><a class="nounderline abstract_t">Raiola AM, Dominietto A, di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant 2014; 20:1573.</a></li><li><a class="nounderline abstract_t">Kharfan-Dabaja M, Mhaskar R, Reljic T, et al. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev 2014; :CD010280.</a></li><li><a class="nounderline abstract_t">Ram R, Yeshurun M, Vidal L, et al. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis. Leuk Res 2014; 38:352.</a></li><li><a class="nounderline abstract_t">Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34:621.</a></li><li><a class="nounderline abstract_t">Hamilton BK, Rybicki L, Dean R, et al. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. Am J Hematol 2015; 90:144.</a></li><li><a class="nounderline abstract_t">Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010; 16:937.</a></li><li><a class="nounderline abstract_t">Chhabra S, Liu Y, Hemmer MT, et al. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant 2019; 25:73.</a></li><li><a class="nounderline abstract_t">Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol 2019; 6:e132.</a></li><li><a class="nounderline abstract_t">Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993; 696:9.</a></li><li><a class="nounderline abstract_t">Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13:136.</a></li><li><a class="nounderline abstract_t">Petric R, Freeman D, Wallace C, et al. Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function. Transplantation 1988; 45:883.</a></li><li><a class="nounderline abstract_t">Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991; 23:2977.</a></li><li><a class="nounderline abstract_t">Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122:128.</a></li><li><a class="nounderline abstract_t">Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11:383.</a></li><li><a class="nounderline abstract_t">Neumann F, Graef T, Tapprich C, et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005; 35:1089.</a></li><li><a class="nounderline abstract_t">Piñana JL, Valcárcel D, Fernández-Avilés F, et al. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings. Bone Marrow Transplant 2010; 45:1449.</a></li><li><a class="nounderline abstract_t">Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014; 49:168.</a></li><li><a class="nounderline abstract_t">Jacobson P, El-Massah SF, Rogosheske J, et al. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44:113.</a></li><li><a class="nounderline abstract_t">Locatelli F, Bernardo ME, Bertaina A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017; 18:1126.</a></li><li><a class="nounderline abstract_t">Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87:3633.</a></li><li><a class="nounderline abstract_t">Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013; 5:211ra157.</a></li><li><a class="nounderline abstract_t">Wachsmuth LP, Patterson MT, Eckhaus MA, et al. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest 2019; 129:2357.</a></li><li><a class="nounderline abstract_t">Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31:1310.</a></li><li><a class="nounderline abstract_t">Robinson TM, O'Donnell PV, Fuchs EJ, Luznik L. Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 2016; 53:90.</a></li><li><a class="nounderline abstract_t">Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010; 47:65.</a></li><li><a class="nounderline abstract_t">Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992; 6:163.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012141s090,012142s112lbl.pdf (Accessed on August 28, 2019).</li><li><a class="nounderline abstract_t">Lorentino F, Labopin M, Ciceri F, et al. Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. Leukemia 2021; 35:585.</a></li><li><a class="nounderline abstract_t">De Jong CN, Meijer E, Bakunina K, et al. Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors [Plenary abstract]. Blood (ASH Annual Meeting Abstracts) 2019; 134.</a></li><li><a class="nounderline abstract_t">O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8:377.</a></li><li><a class="nounderline abstract_t">Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115:3224.</a></li><li><a class="nounderline abstract_t">Kanakry CG, Tsai HL, Bolaños-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 2014; 124:3817.</a></li><li><a class="nounderline abstract_t">Mielcarek M, Furlong T, O'Donnell PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 2016; 127:1502.</a></li><li><a class="nounderline abstract_t">Wagner JE, Thompson JS, Carter SL, et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005; 366:733.</a></li><li><a class="nounderline abstract_t">Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106:3308.</a></li><li><a class="nounderline abstract_t">Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012; 30:3194.</a></li><li><a class="nounderline abstract_t">Bleakley M, Sehgal A, Seropian S, et al. Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. J Clin Oncol 2022; 40:1174.</a></li><li><a class="nounderline abstract_t">Watkins B, Qayed M, McCracken C, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol 2021; 39:1865.</a></li><li><a class="nounderline abstract_t">Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 2014; 124:1174.</a></li><li><a class="nounderline abstract_t">Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20:640.</a></li><li><a class="nounderline abstract_t">Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med 2012; 209:903.</a></li><li><a class="nounderline abstract_t">Simms-Waldrip T, Meir M, Fan D, et al. The role of gut microbiota in the development of intestinal GVHD (abstract 53). Biol Blood Marrow Transplant 2014; 20:S55.</a></li><li><a class="nounderline abstract_t">Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med 2020; 382:822.</a></li><li><a class="nounderline abstract_t">Beelen DW, Elmaagacli A, Müller KD, et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93:3267.</a></li><li><a class="nounderline abstract_t">Przepiorka D, Ippoliti C, Khouri I, et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 88:4383.</a></li><li><a class="nounderline abstract_t">Santos G, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1:21.</a></li><li><a class="nounderline abstract_t">Ramsay NK, Kersey JH, Robison LL, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982; 306:392.</a></li><li><a class="nounderline abstract_t">Forman SJ, Blume KG, Krance RA, et al. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone. Transplant Proc 1987; 19:2605.</a></li><li><a class="nounderline abstract_t">Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 1993; 329:1225.</a></li><li><a class="nounderline abstract_t">Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77:1821.</a></li><li><a class="nounderline abstract_t">Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70:1382.</a></li><li><a class="nounderline abstract_t">Chang YJ, Xu LP, Wang Y, et al. Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. J Clin Oncol 2016; 34:1855.</a></li><li><a class="nounderline abstract_t">Ruutu T, Nihtinen A, Niittyvuopio R, et al. A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis. Cancer 2018; 124:727.</a></li><li><a class="nounderline abstract_t">Quellmann S, Schwarzer G, Hübel K, et al. Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis. Leukemia 2008; 22:1801.</a></li><li><a class="nounderline abstract_t">Glass B, Hasenkamp J, Wulf G, et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15:757.</a></li><li><a class="nounderline abstract_t">Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994; 372:570.</a></li><li><a class="nounderline abstract_t">Altmeyer A, Dumont FJ. Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. Cytokine 1993; 5:133.</a></li><li><a class="nounderline abstract_t">Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014; 124:1372.</a></li><li><a class="nounderline abstract_t">Cieri N, Greco R, Crucitti L, et al. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biol Blood Marrow Transplant 2015; 21:1506.</a></li><li><a class="nounderline abstract_t">Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008; 112:4425.</a></li><li><a class="nounderline abstract_t">Rodriguez R, Nakamura R, Palmer JM, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood 2010; 115:1098.</a></li><li><a class="nounderline abstract_t">Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109:3108.</a></li><li><a class="nounderline abstract_t">Armand P, Gannamaneni S, Kim HT, et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767.</a></li><li><a class="nounderline abstract_t">Pulsipher MA, Langholz B, Wall DA, et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood 2014; 123:2017.</a></li><li><a class="nounderline abstract_t">Hatano R, Ohnuma K, Yamamoto J, et al. CD26-mediated co-stimulation in human CD8(+)  T cells provokes effector function via pro-inflammatory cytokine production. Immunology 2013; 138:165.</a></li><li><a class="nounderline abstract_t">Ohnuma K, Yamochi T, Uchiyama M, et al. CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci U S A 2004; 101:14186.</a></li><li><a class="nounderline abstract_t">Farag SS, Abu Zaid M, Schwartz JE, et al. Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease. N Engl J Med 2021; 384:11.</a></li><li><a class="nounderline abstract_t">Farag SS, Srivastava S, Messina-Graham S, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 2013; 22:1007.</a></li><li><a class="nounderline abstract_t">Farag SS, Nelson R, Cairo MS, et al. High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation. Oncotarget 2017; 8:110350.</a></li><li><a class="nounderline abstract_t">Kennedy GA, Tey SK, Buizen L, et al. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood 2021; 137:1970.</a></li><li><a class="nounderline abstract_t">Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol 2014; 15:1451.</a></li><li><a class="nounderline abstract_t">Drobyski WR, Szabo A, Zhu F, et al. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica 2018; 103:717.</a></li></ol></div><div id="topicVersionRevision">Topic 3542 Version 40.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25529383" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22410750" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32004485" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3513012" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3521761" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2673331" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1543946" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2207450" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728315" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547942" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979948" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21421070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26437063" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9746768" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27951736" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972135" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26735993" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26723083" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19695955" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28583289" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27758821" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261255" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18489989" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25267759" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25797174" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24910379" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25061777" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24418750" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300236" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25353395" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102746" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153491" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30824040" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509138" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The mechanism of action of FK-506 and cyclosporin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374612" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The mechanism of action of cyclosporin A and FK506.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3368946" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of cyclosporine on urinary prostanoid excretion, renal blood flow, and glomerulotubular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1721333" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823354" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846292" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821769" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20140024" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892326" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19151792" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28705454" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8611687" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Malignant neoplasms following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24225944" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30913039" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23423745" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27000732" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20066512" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1422285" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1422285" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32409688" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors [Plenary abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12171484" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124511" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25316679" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26764356" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125590" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16046530" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869882" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35007144" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449816" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24939656" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24492144" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation: loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547653" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of gut microbiota in the development of intestinal GVHD (abstract 53)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32101664" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233878" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8943876" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cyclosporine plus methylprednisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: A randomized double-blind study in patients undergoing allogeneic marrow transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7035950" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A randomized study of the prevention of acute graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3079090" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413388" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2015405" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3311203" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27091717" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112242" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18449206" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Corticosteroids in the prevention of graft-vs-host disease after allogeneic myeloablative stem cell transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827808" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7990932" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7687472" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982504" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26001696" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776081" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19965688" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17138818" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001324" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497539" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23113658" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : CD26-mediated co-stimulation in human CD8(+)  T cells provokes effector function via pro-inflammatory cytokine production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15353589" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33406328" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23270493" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29299152" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33512442" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25456364" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29351985" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
